Editorial: Identification of effective biomarkers for diagnosis and treatment of chronic kidney disease: integrating bioinformatics and pharmacological approaches

Editorial: Identification of effective biomarkers for diagnosis and treatment of chronic kidney disease: integrating bioinformatics and pharmacological approaches

Saved in:

Bibliographic Details
Main Authors:	Swayam Prakash Srivastava, Keizo Kanasaki
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Series:	Frontiers in Pharmacology
Subjects:	chronic kidney disease network phamacology drug-drug interaction molecular docking SGLT-2 inhibitor ANGPTL4
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1606173/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

General practice variation in peptic ulcer prophylaxis: a nationwide register-based study
by: Peter Fentz Haastrup, et al.
Published: (2025-01-01)

SGLT2 inhibitor downregulates ANGPTL4 to mitigate pathological aging of cardiomyocytes induced by type 2 diabetes
by: Yun Wen, et al.
Published: (2024-12-01)

New Therapies on the Horizon for Preventing the Progression of Chronic Kidney Disease in Childhood
by: Siobhan Wagner, et al.
Published: (2023-12-01)

Identification of novel HER2 ınhibitors: potential therapeutics for breast cancer
by: Cem Yalaza, et al.
Published: (2025-06-01)

Repurposing raltegravir for reducing inflammation and treating cancer: a bioinformatics analysis
by: Zahra Nikfarjam, et al.
Published: (2024-12-01)

Editorial: Diabetic kidney disease: routes to drug development, pharmacology and underlying molecular mechanisms, volume II
by: Divya Bhatia, et al.
Published: (2025-04-01)

Dual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG)
by: Amin Roshdy Soliman, et al.
Published: (2025-06-01)

Oxidative stress-related biomarkers in thyroid eye disease: evidence from bioinformatics analysis and experimental validation
by: Yuanping Hai, et al.
Published: (2025-08-01)

Assessment of Gliflozins prescribing pattern in a United Arab Emirates tertiary-level care hospital
by: Wessa Shenouda, et al.
Published: (2025-04-01)

Advances in the mechanism of action of SGLT2 inhibitors on the kidney
by: JI Ying, et al.
Published: (2020-01-01)

Identification of new candidate molecules against SARS-CoV-2 through docking studies
by: Punar Aliyeva, et al.
Published: (2025-05-01)

Structural bioinformatics for rational drug design
by: Soroush Mozaffari, et al.
Published: (2025-01-01)

Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails
by: O. Y. Sukhareva, et al.
Published: (2022-02-01)

Identification of lurasidone as a potent inhibitor of severe fever with thrombocytopenia syndrome virus by targeting the viral nucleoprotein
by: Ting Cheng, et al.
Published: (2025-04-01)

Bioinformatics-Driven Structural and Pharmacological Analysis of SLITRK1 in Tourette Syndrome: Impact of S656M Mutation Using Molecular Dynamics, Docking, and Reinforcement Learning
by: Emre Aktaş, et al.
Published: (2025-01-01)

Multilayer regulation of postprandial triglyceride metabolism in response to acute cold exposure
by: Yiliang Zhang, et al.
Published: (2025-03-01)

Editorial: Approaches to improve the performance of virtual screening: scoring functions, structural filtration, prediction of physicochemical properties/pharmacological activity
by: Hélcio Silva Dos Santos, et al.
Published: (2025-08-01)

In Silico and In Vivo Evaluation of a New Derivative from Memantine and Sinapic Acid (<i>N</i>-Sinapoyl-memantine) as a Candidate for the Management of Alzheimer’s Disease
by: Andrey Popatanasov, et al.
Published: (2025-05-01)

Evaluating Guideline Alignment by Analyzing Patient Profiles of Elderly People with Type 2 Diabetes and Chronic Kidney Disease Treated or Not with SGLT2 Inhibitors
by: Kyriaki Vafeidou, et al.
Published: (2025-05-01)

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
by: Gilda M. Portalatin, et al.
Published: (2025-01-01)

SGLT2 inhibitors in preventing progression of chronic kidney disease in patients with type 2 diabetes: a literature review
by: Michał Szczepański, et al.
Published: (2024-12-01)

A Search for FDA Approved Drugs with Multiple Antiemetic Targets: A Computational-Based Drug Repositioning Study
by: Abdulmajeed Yunusa*1, Albashir Tahir1,2
Published: (2025-05-01)

Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial
by: Akihiko Koshino, et al.
Published: (2024-02-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

Lipid Profile, PCSK9, ANGPTL3 and Lipoprotein (a) Levels in Men Diagnosed With Localized High‐Grade Prostate Cancer and Men At‐Risk of Prostate Cancer
by: Ann‐Charlotte Bergeron, et al.
Published: (2025-02-01)

Design, Synthesis, Anticancer Evaluation and Molecular Docking of Pyrimidine, Pyrido[4,3-d]pyrimidine and 5,6,7,8-Tetrahydropyrido[3,4-d]pyrimidine Derivatives as Novel KRAS-G12D Inhibitors and PROTACs
by: Hailong Yang, et al.
Published: (2025-05-01)

Molecular modeling, synthesis and biological evaluation of caffeic acid based Dihydrofolate reductase inhibitors
by: Renu Sehrawat, et al.
Published: (2024-12-01)

Identification of Potential Inhibitors Targeting Non-Structural Proteins NS3 and NS5 of Dengue Virus Using Docking and Deep Learning Approaches
by: Alomgir Hossain, et al.
Published: (2025-04-01)

Effects of sotagliflozin on kidney and cardiac outcome in a hypertensive model of subtotal nephrectomy in male mice
by: Helen Goodluck, et al.
Published: (2025-04-01)

Glucagon like peptide-1 modulates urinary sodium excretion in diabetic kidney disease via ENaC activation
by: Goh Kodama, et al.
Published: (2025-04-01)

Dapagliflozin in Chronic Kidney Disease: Insights from Network Pharmacology and Molecular Docking Simulation
by: Atthaphong Phongphithakchai, et al.
Published: (2025-03-01)

Integrating network pharmacology, IPA, and molecular docking to reveal the anti-osteoporosis effects of EA and EB via the FAK pathway
by: Ziheng Wei, et al.
Published: (2025-07-01)

The Effects of SGLT2 Inhibitors on Lipid Profile and Kidney Function in Patients with Chronic Kidney Disease Regardless of Diabetes and Hypertension Status
by: Selena Gajić, et al.
Published: (2025-04-01)

Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome
by: Juan Guerrero-Mauvecin, et al.
Published: (2025-06-01)

Identification of druggable targets in acute kidney injury by proteome- and transcriptome-wide Mendelian randomization and bioinformatics analysis
by: Jiachen Liu, et al.
Published: (2025-03-01)

Sodium-glucose cotransporter 2 inhibitors in chronic kidney disease: A review of current evidence and clinical implications
by: Abdulrahman Saad Alfaiz
Published: (2025-06-01)

The Influence of Performance Status, Inflammation, and Nutrition on the Impact of SGLT2 Inhibitors on Cancer Outcomes
by: Diego Rivas‐Otero, et al.
Published: (2025-03-01)

Pharmacological Evaluation of active compounds in papaya associated with thrombocytopenia inhibition in dengue patients through in silico approaches
by: Md. Anisur Rahman, et al.
Published: (2025-07-01)

The association of lipids and novel non-statin lipid-lowering drug target with osteoporosis: evidence from genetic correlations and Mendelian randomization
by: Qingcong Zheng, et al.
Published: (2025-02-01)

Inhibition of sodium‐glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis‐related kidney disease
by: Takuro Nagoya, et al.
Published: (2019-12-01)